Beyond Gradient, Beyond Flow: Rethinking Risk Stratification in Aortic Stenosis Authors: Kimberley I. Hemelrijk, Hugo M. Aarts, Gijs M. Broeze, Astrid C. van Nieuwkerk, Ronak Delewi Published: 2026 We thank Dr. Shah for the thoughtful comments on our study evaluating clinical outcomes across discordant aortic stenosis (AS) phenotypes in a large multicenter cohort of patients undergoing transcatheter aortic valve replacement (TAVR).1 Our analysis of 15,233 patients from the CENTER2 data set demonstrated that 1 in 5 patients undergoing TAVR present with discordant AS. Although all-cause mortality did not differ between discordant and concordant high-gradient AS, heterogeneity was observed across subgroups. In particular, patients with low-gradient AS and impaired left ventricular ejection fraction (LVEF) exhibited higher 1-year mortality, whereas outcomes in those with low-gradient AS and preserved LVEF were comparable to concordant high-gradient AS. Identifying echocardiographic variables that adequately capture the clinically relevant aspects of AS remain challenging, as each parameter reflects only part of a complex pathophysiological spectrum. Shah highlights the role of stroke volume index (SVi) as a flow-based discriminator of risk. SVi is indeed an important physiological determinant, and discordant AS phenotypes are (at least in part) explained by low-flow states. However, SVi is closely linked to left ventricular function and loading conditions, and therefore reflect a broader hemodynamic profile rather than serving as an isolated mechanistic marker. In the CENTER2 cohort, patients with low-gradient AS and impaired LVEF had worse outcomes than those with preserved function, underscoring that ventricular dysfunction remains an important prognostic factor of adverse clinical outcomes.2 As both transvalvular gradients and SVi have inherent limitations, additional parameters have been proposed to allow for a more adequate assessment of AS severity. The recently proposed stress aortic valve index, which quantifies the relative reduction in maximal flow during stress, showed only modest agreement with conventional echocardiographic measures of AS severity, although it was associated with clinical outcomes.3 These findings support a shift toward a more holistic approach to risk stratification, integrating complementary parameters rather than relying on a single metric. In line with this broader approach, we share Shah's view that cardiac damage staging offers a promising complementary framework for risk stratification and has strong prognostic implications.4,5 Cardiac damage staging supports the idea to look beyond the aortic valve and adopts a more comprehensive approach by incorporating structural cardiac damage. This framework may be particularly relevant in patients with asymptomatic AS in whom earlier TAVR may preserve myocardial function and allow for greater recovery.6 Ultimately, our study shows that many patients undergoing TAVR have discordant gradients. Improved recognition and characterization of discordant AS has the potential to directly improve patient care by supporting more accurate risk stratification, timelier referral, and individualized treatment decisions, thereby reducing delays in intervention and preventing progression to irreversible cardiac damage. As Dr Shah proposes, prospective studies with systematic collection of flow parameters (including SVi), as well as ventricular function and cardiac damage staging are needed to (1) determine whether flow-guided or stage-guided strategies improve patient outcomes and (2) better define the optimal timing of intervention in this high-risk population. Funding This study received support from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation (CVON 2018-28 & 2012-06 Heart Brain Connection), the Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences. Disclosure Statement Professor Ronak Delewi received educational grants from Boston Scientific, Abiomed, Edwards Lifesciences, Sanofi, Meril life Science, Novartis, and Amgen. The other authors had no conflicts to declare.